Liver Cancer

Lenvatinib Noninferior to Sorafenib in Advanced Hepatocellular Carcinoma: Results from the REFLECT Clinical Trial

Walter Alexander

Liver Cancer

Chicago, IL—Beyond demonstrating noninferiority for overall survival (OS) in advanced, unresectable hepatocellular carcinoma (HCC), lenvatinib (Lenvima) demonstrated superiority over sorafenib (Nexavar) in progression-free survival (PFS), time to progression, and overall response rate in the REFLECT clinical trial, reported lead investigator Ann-Lii Cheng, MD, National Taiwan University Hospital, Taipei, in an oral presentation at the 2017 ASCO annual meeting. With nearly 745,000 deaths attributed to HCC annually, HCC is the second leading cause of death worldwide, noted Dr Cheng. [ Read More ]